ABIOのチャート
ABIOの企業情報
| symbol | ABIO |
|---|---|
| 会社名 | ARCA biopharma Inc. （ARCAバイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: In Vitro_In Vivo Diagnostic Substances |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 エーアルシーエー・バイオファマ（ARCA biopharma Inc.）は主に心不全及びその他心臓血管疾患のための遺伝子をターゲットにした治療法の開発に従事するバイオ医薬品企業。同社の主要候補製品の「Gencaro TM（ブシンドロール塩酸塩）」は、慢性心不全（HF）治療のために開発されている薬理学的特性を持つβ［ベータ］遮断薬及び血管拡張剤である。同社はLabCorp社と提携して、「Gencaro」に対する臨床反応を予測できる遺伝子マーカーのためのコンパニオン・テストであるGencaroテストを行っていた。同社の候補製品は「Gencaro（ブシンドロール塩酸塩）」は、慢性心不全（HF）治療のために開発されている薬理学的特性を持つβ［ベータ］遮断薬及び血管拡張剤である。「Gencaro」は心臓神経系においてβ-1とβ-2両方の受容体を遮断する性質を持っているため、β遮断薬クラスの化合物の一部として見なされる。これらの受容体の遮断を通して、「Gencaro」はこれらの受容体を活性化する用のその他分子との結合を防ぐ。 ARCAバイオファ―マは、米国のバイオ医薬品企業。心血管疾患の遺伝的標的治療の開発を中心に事業を展開。主要製品候補として、心不全および左心室機能障害の患者向けに心房細動治療のためのβ遮断薬、および軽度の血管拡張剤であるGencaro（ブシンドロ―ル塩酸塩）の開発を手掛ける。 ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement for a single Phase 3 clinical trial. ARCA is also developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically targeted treatment for heart failure and peripheral arterial disease. |
| 本社所在地 | 11080 CirclePoint Road Suite 140 Westminster CO 80020 USA |
| 代表者氏名 | Robert E. Conway ロバート・E・コンウェイ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 720-940-2200 |
| 設立年月日 | 33817 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 14人 |
| url | http://arcabio.com/ |
| nasdaq_url | https://www.nasdaq.com/symbol/abio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -13.67700 |
| 終値（lastsale） | 0.6301 |
| 時価総額（marketcap） | 8773402.1325 |
| 時価総額 | 時価総額（百万ドル） 8.61467 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -1.02033 |
| 当期純利益 | 当期純利益（百万ドル） -13.48100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Arca Biopharma Inc revenues was not reported. Net loss decreased 51% to $4.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.07 to -$0.35. |
ABIOのテクニカル分析
ABIOのニュース
ARCA biopharma, Inc. (NASDAQ:ABIO) Short Interest Update 2023/04/01 06:20:41 The AM Reporter
ARCA biopharma, Inc. (NASDAQ:ABIO – Get Rating) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 226,300 shares, a drop of 7.1% from the February 28th total of 243,500 shares. Based on an average daily volume of 38,700 shares, the short-interest ratio is […]
ARCA biopharma Announces 2022 Financial Results and 2023/02/24 21:20:00 businessfortnight.com
WESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today […] The post ARCA biopharma Announces 2022 Financial Results and appeared first on Businessfortnight .
ARCA biopharma GAAP EPS of -$0.16 (NASDAQ:ABIO) 2022/10/28 20:18:04 Seeking Alpha
ARCA biopharma press release (ABIO): Q3 GAAP EPS of -$0.16.Cash and cash equivalents were $43.9 million as of September 30, 2022, compared to $53.4 million as of December 31, 2021
ARCA biopharma Announces Third Quarter 2022 Financial Results 2022/10/28 20:15:00 GlobeNewswire
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options
ARCA biopharma GAAP EPS of -$0.22 (NASDAQ:ABIO) 2022/08/02 21:15:58 Seeking Alpha
ARCA biopharma press release (NASDAQ:ABIO): Q2 GAAP EPS of -$0.22.
ARCA biopharma Announces 2022 Financial Results and 2023/02/24 21:20:00 businessfortnight.com
WESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today […] The post ARCA biopharma Announces 2022 Financial Results and appeared first on Businessfortnight .
ARCA biopharma GAAP EPS of -$0.16 (NASDAQ:ABIO) 2022/10/28 20:18:04 Seeking Alpha
ARCA biopharma press release (ABIO): Q3 GAAP EPS of -$0.16.Cash and cash equivalents were $43.9 million as of September 30, 2022, compared to $53.4 million as of December 31, 2021
ARCA biopharma Announces Third Quarter 2022 Financial Results 2022/10/28 20:15:00 GlobeNewswire
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options
ARCA biopharma GAAP EPS of -$0.22 (NASDAQ:ABIO) 2022/08/02 21:15:58 Seeking Alpha
ARCA biopharma press release (NASDAQ:ABIO): Q2 GAAP EPS of -$0.22.
ARCA biopharma Announces Second Quarter 2022 Financial Results 2022/08/02 20:15:00 GlobeNewswire
WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update.
ARCA biopharma GAAP EPS of -$0.22 (NASDAQ:ABIO) 2022/08/02 21:15:58 Seeking Alpha
ARCA biopharma press release (NASDAQ:ABIO): Q2 GAAP EPS of -$0.22.
ARCA biopharma Announces Second Quarter 2022 Financial Results 2022/08/02 20:15:00 GlobeNewswire
WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update.
ARCA biopharma: Pressure May Make This A Liquidation Play (NASDAQ:ABIO) 2022/05/03 15:50:48 Seeking Alpha
Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Click here to learn more about ABIO stock.
ARCA biopharma GAAP EPS of -$0.23 (NASDAQ:ABIO) 2022/05/02 20:57:31 Seeking Alpha
ARCA biopharma press release (ABIO): Q1 GAAP EPS of -$0.23.Cash and cash equivalents were $49.1 million as of March 31, 2022, compared to $53.4 million as of December 31, 2021
ARCA biopharma Announces First Quarter 2022 Financial Results 2022/05/02 20:15:00 GlobeNewswire
WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update.